HAEMONETICS CORP — Director's Dealing 2019

Oct 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-10-01

Reporting Person: Burke William P. Mr. (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-01	Common Stock	M	5718	$41.64	Acquired	20178	Direct
2019-10-01	Common Stock	S	3070	$124.47	Disposed	17108	Direct
2019-10-01	Common Stock	S	1309	$125.71	Disposed	15799	Direct
2019-10-01	Common Stock	S	1670	$126.72	Disposed	14129	Direct
2019-10-01	Common Stock	S	648	$127.80	Disposed	13481	Direct
2019-10-01	Common Stock	S	467	$128.66	Disposed	13014	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-01	Non-qualified Stock Option (Right to Buy)	$41.64	M	5718	Disposed	2024-06-06	Common Stock (5718)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested RSUs previously reported.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.21 to $124.98, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.24 to $126.16, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.29 to $127.18, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.31 to $127.99, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.55 to $129.00, inclusive.

F8: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.